Business
Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases
Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license agreement with Sanofi for a tri-specific T-cell engager, which has the potential to treat a broad range of B cell-mediated autoimmune diseases.
About this update from Sanofi Sa
[{"type":"text","content":"SAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license agreement with Sanofi for a tri-specific T-cell engager, which has the potential to treat a broad range of B cell-mediated autoimmune diseases.","length":361,"tagName":"p"},{"type":"image","alt":"Kali Tx Logo (PRNewsfoto/Kali Therapeutics)","displaySize":"","headline":null,"caption":"Kali Tx Logo (PRNewsfoto/Kali Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":390,"url":"https://media.zenfs.com/en/prnewswire.com/f6bdf7b2e15f39c97382605883ecc1fa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n28HImLN_0Zfhsr3D6WHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY4Nw--/https://media.zenfs.com/en/prnewswire.com/f6bdf7b2e15f39c97382605883ecc1fa","width":400,"height":390}},"href":"https://mma.prnewswire.com/media/2934825/Kali_square_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the agreement, Sanofi will obtain exclusive worldwide rights to KT501, a novel tri-specific antibody utilizing Kali Therapeutics' proprietary discovery and research platform. KT501 is being evaluated in a first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics in participants with Rheumatoid Arthritis. Kali Therapeutics will receive upfront and near-term payments totaling $180 million. Kali Therapeutics is also eligible to receive up to a total of $1.05 billion in development and commercial milestone payments and tiered royalties on product sales ranging from the high-single to double digits.","length":673,"tagName":"p"},{"type":"text","content":""We are thrilled to collaborate with Sanofi, a global leader in immunology, to advance the development of KT501, our lead tri-specific program," said Weihao Xu, CEO of Kali Therapeutics. "Our platform leverages state-of-the-art protein engineering to solve complex therapeutic challenges. This collaboration highlights the potential of our unique CD3 masking technology to decouple potency from toxicity, aiming to provide safer, more effective options for patients."","length":492,"tagName":"p"},{"type":"text","content":"Weihao Xu, CEO o...